SITC Cancer Immunotherapy Guideline – Acute Leukemia Webinar: Continuing Education Credits

Joint Accreditation Statement

thumbnail image
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-21-2550-L01-P

Type of Activity: Application

 

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses. 



Hardware/Software Requirements
The webinar is accessed through Zoom. An internet connection and the system requirements are needed to access the webinar.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Learning Objectives

Upon completion of this program, participants will be able to:

  • Describe recommended uses of immunotherapies for acute leukemia as outlined in the SITC clinical practice guidelines
  • Identify opportunities to incorporate cancer immunotherapy into clinical practice
  • Appropriately manage common and uncomplicated toxicities associated with immunotherapy for acute leukemia 

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer
Postgraduate Institute for Medicine SITC Logo
  
This webinar is supported, in part, by independent medical education grants from
Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.